Inactive Instrument

AVEO Pharmaceuticals, Inc.

AVEO

US0535883070

AVEO Completes Acquisition by LG Chem

Published on 01/20/2023 at 09:09 am GMT - Modified on 01/20/2023 at 09:17 am GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AVEO Pharmaceuticals, Inc.

01-14	AVEO Oncology Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab	CI
18/02/25	AVEO Oncology Presents Two Posters for Tivozanib at the 2025 ASCO GU Meeting	CI
16/09/24	AVEO Pharmaceuticals, Inc. Presents TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024	CI
18/07/24	Aveo Oncology Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results	CI
13/06/24	LG Chem Company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound Enters Phase 1 Clinical Study, Dosing Initiated in the U.S	CI
25/03/24	AVEO Pharmaceuticals, Inc. Announces Executive Changes	CI
06/02/24	Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist	CI
16/01/24	AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)	CI
27/06/23	AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma	CI
20/01/23	South Korean Stocks Climb on Demand Recovery Hopes from China; LG Chem Stocks Add 1%	MT
20/01/23	AVEO Completes Acquisition by LG Chem	MT
20/01/23	LG Chem Acquires US Biopharma Firm AVEO Pharmaceuticals	MT
19/01/23	AVEO Pharmaceuticals, Inc. Announces Management Changes	CI
19/01/23	AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer	CI
19/01/23	AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from NASDAQ Composite Index	CI
19/01/23	AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index	CI
19/01/23	AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P TMI Index	CI
18/01/23	LG Chem, Ltd. completed the acquisition of AVEO Pharmaceuticals, Inc. from a group of shareholders.	CI
18/01/23	AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger	MT
06/01/23	AVEO Pharmaceuticals Stockholders Approve LG Chem Merger	MT
09/11/22	North American Morning Briefing : Midterm Outcome -3-	DJ
08/11/22	Stifel Downgrades AVEO Pharmaceuticals to Hold From Buy, Price Target is $15	MT
07/11/22	Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q3 Revenue $30.4M, vs. Street Est of $29.9M	MT
07/11/22	AVEO Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
07/11/22	Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022	CI

Chart AVEO Pharmaceuticals, Inc.

Duration

Period

AVEO: Dynamic Chart

AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company's commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company's pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).

Employees

114

Sector

Pharmaceuticals

More about the company